GHRP-6
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
Key Takeaway
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and the original member of the GHRP family, first synthesized in the 1980s as part of the search for orally active GH secretagogues. It was the compound that established the GHRP drug class and led to the eventual development of GHRP-2, ipamorelin, hexarelin, and the oral ghrelin mimetic MK-677. GHRP-6 acts as a full agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), producing robust GH release alongside the most pronounced appetite stimulation of any injectable GHRP.
This intense hunger effect, caused by potent central ghrelin receptor activation, makes GHRP-6 the compound of choice for individuals struggling to eat enough calories, whether due to illness, extremely high metabolic demands, or recovery from muscle-wasting conditions. For users who do not need appetite stimulation, the appetite effect is a significant drawback, and other GHRPs offer similar GH stimulation with less interference with hunger control (PMID: 9467542). GHRP-6 also produces measurable cortisol and prolactin elevation, more so than ipamorelin but similar to GHRP-2.
| Type | Growth Hormone |
| FDA Status | Research Only |
| Evidence Level | Moderate |
| Typical Dose | 100-300 mcg per injection |
| Frequency | 2-3 times daily on an empty stomach |
| Cycle Length | 8-12 weeks, followed by a 4-week break |
| Key Goals | muscle-growth, recovery, anti-aging |
How it works
GHRP-6 is a full agonist at the ghrelin receptor (GHS-R1a), a G protein-coupled receptor expressed in the anterior pituitary, hypothalamus, and multiple peripheral tissues including the stomach, heart, and adrenal glands. Receptor binding triggers a phospholipase C signaling cascade and intracellular calcium release, which stimulates somatotroph cells in the anterior pituitary to release growth hormone. Simultaneously, GHRP-6 acts at hypothalamic GHS-R1a to stimulate endogenous GHRH secretion and suppress somatostatin, the inhibitory neuropeptide that restrains GH release. This combined pituitary and hypothalamic action produces GH pulses that are substantially amplified when a GHRH analog is co-administered (PMID: 7928953).
The defining pharmacological characteristic of GHRP-6 compared to newer GHRPs is its full ghrelin-mimetic activity. Ghrelin, the endogenous ligand for GHS-R1a, is produced primarily by the stomach and serves as the body's primary hunger signal. GHRP-6's high receptor affinity and full agonist activity at GHS-R1a replicates the appetite-stimulating dimension of ghrelin signaling more completely than GHRP-2 or ipamorelin do. The result is intense, predictable hunger that begins within 15 to 20 minutes of injection and persists for 1 to 3 hours. For clinical and research contexts focused on appetite stimulation (cachexia, anorexia, recovery from illness), this property is the primary therapeutic target, not a side effect (PMID: 8421073).
GHRP-6 also activates GHS-R1a in adrenal cortex cells and pituitary lactotrophs, producing transient cortisol and prolactin elevation after each injection. These hormonal responses are dose-dependent and return to baseline within 2 to 3 hours. The cortisol elevation is mediated through GHS-R1a signaling in adrenocortical cells rather than through hypothalamic-pituitary-adrenal axis stimulation, meaning it is a direct receptor effect rather than a stress response. Prolactin elevation is similarly direct, via GHS-R1a on lactotroph cells, and is transient in single-dose protocols.
Benefits
- Produces potent GH pulses through dual pituitary and hypothalamic stimulation, with peak GH concentrations occurring 15 to 60 minutes post-injection in a pattern consistent with natural pulsatile GH secretion (PMID: 9467542)
- Strongest appetite stimulation of any injectable GHRP, driven by full agonist activity at hypothalamic ghrelin receptors. This effect is clinically relevant for muscle-wasting conditions, cachexia, and individuals who struggle to maintain adequate caloric intake during aggressive training programs (PMID: 8421073)
- GH-mediated lipolysis supports body fat reduction over sustained cycles, while elevated IGF-1 from downstream GH signaling promotes protein synthesis and lean mass development
- Recovery enhancement through GH-driven collagen synthesis and tissue repair, with anecdotal reports of improved joint comfort and faster recovery from training consistent with GH's established role in connective tissue maintenance
- Synergistic GH amplification when combined with a GHRH analog such as CJC-1295 or modified GRF(1-29), as the GHRH analog primes the pituitary while GHRP-6 simultaneously suppresses somatostatin (PMID: 7928953)
- Potential utility in appetite restoration for individuals recovering from illness, cancer treatment, or other conditions associated with reduced appetite and muscle wasting, where ghrelin-mediated hunger stimulation is a therapeutic goal
- Sleep quality improvements through GH-mediated slow-wave sleep enhancement, which is particularly notable with the pre-sleep dose timing common in research protocols
- Historical significance as the foundational GHRP: GHRP-6 has the longest research history in the class, with studies dating to the early 1980s, providing a more extensive safety and efficacy data foundation than newer GHRPs
Clinical comparisons
GHRP-6 is the original GHRP, and its successors were developed specifically to address its limitations. GHRP-2 produces comparable GH stimulation with meaningfully less appetite stimulation and slightly less cortisol elevation, making it the preferred GHRP for most GH-focused protocols that do not specifically require appetite enhancement. Ipamorelin is the most selective GHRP, producing significant GH pulses with negligible cortisol and prolactin elevation and minimal appetite effects.
Hexarelin exceeds GHRP-6 in raw GH output but produces the fastest desensitization and the heaviest cortisol burden. MK-677 (ibutamoren) replicates much of GHRP-6's mechanism in an oral form with 24-hour activity, producing persistent GH and IGF-1 elevation and persistent appetite stimulation, which makes it the oral alternative for bulking protocols where appetite stimulation is a feature rather than a drawback.
Side effects
- Intense appetite stimulation: The most notable and predictable side effect of GHRP-6. Hunger begins within 15 to 20 minutes of injection and can be quite severe, particularly at doses above 200 mcg. Users who do not need appetite enhancement often find this effect difficult to manage, especially with multiple daily injections. Timing injections directly before planned meals is the standard mitigation strategy
- Cortisol elevation: GHRP-6 produces transient cortisol increases with each injection, peaking around 30 minutes and resolving within 2 to 3 hours. High-frequency dosing (3 or more times daily) can produce cumulative cortisol exposure that impairs recovery or disrupts sleep. GHRP-6 typically produces more cortisol elevation than GHRP-2 at equivalent doses
- Prolactin elevation: Measurable prolactin increases follow GHRP-6 injection through GHS-R1a activation in pituitary lactotrophs. Chronic prolactin elevation across prolonged or high-dose protocols may contribute to gynecomastia risk in men or menstrual irregularities in women
- Water retention: GH elevation drives fluid retention through interactions with aldosterone and antidiuretic hormone. Mild to moderate bloating and peripheral edema are common during the first 2 to 4 weeks of use and typically diminish as the body adapts
- Injection site reactions: Localized redness, swelling, or mild pain at subcutaneous injection sites, particularly with repeated injections in the same location. Rotating sites across the abdomen reduces this effect
- Tingling or numbness: Transient peripheral tingling, most commonly in the hands, occurring in association with GH elevation and related fluid shifts. Typically mild and self-resolving within hours
- Potential for compulsive eating or overeating: Unlike GHRP-2's moderate hunger signal, GHRP-6's appetite stimulation can be difficult to distinguish from genuine hunger, potentially leading to excessive caloric intake if meal timing is not carefully planned around injections
Dosing protocol
Typical Dose
100-300 mcg per injection
Frequency
2-3 times daily on an empty stomach
Cycle Length
8-12 weeks, followed by a 4-week break
Inject subcutaneously, typically into the abdomen, at least 2 hours after the previous meal. Wait 20 to 30 minutes after injection before eating to avoid insulin-mediated blunting of the GH response. The intense hunger that follows within 15 to 20 minutes of injection makes pre-meal timing essential for practical compliance. Users who inject in a fasted state and then eat a high-protein meal capitalize on the anabolic window created by simultaneous GH elevation and nutrient availability. The most common timing windows are morning (fasted upon waking), pre-workout (45 to 60 minutes before training), and pre-sleep (2 hours after last meal). Stacking with a GHRH analog such as CJC-1295 or modified GRF(1-29) substantially amplifies GH output and is standard practice in research protocols. Users who find GHRP-6's appetite effect unmanageable should consider GHRP-2, which produces similar GH stimulation with notably less appetite stimulation, or ipamorelin, which is the most selective GHRP with minimal appetite and cortisol effects.
Deeper on GHRP-6
Full breakdowns of every part of the GHRP-6 research base.
What you will need
Basic supplies for reconstitution and subcutaneous injection.
This page contains affiliate links. Learn more
Bacteriostatic Water (30mL)
$8-15Required for reconstituting lyophilized peptides. 30mL is standard.
Insulin Syringes (1mL, 29ga)
$12-20 (100ct)1mL insulin syringes with 29-gauge needles for subcutaneous injection.
Alcohol Prep Pads
$5-10 (200ct)Sterile 70% isopropyl alcohol wipes for injection site prep.
Sharps Container
$8-15FDA-cleared sharps disposal container for used needles.
Get the GHRP-6 cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Key research
Comparison of growth hormone (GH)-releasing peptides: stimulation of GH release from perifused rat anterior pituitaries by GHRP-1, GHRP-2, GHRP-6, hexarelin, and MK-0677
Endocrinology (1997) — PubMed
Direct comparison of GHRP potency across the class established GHRP-6's relative GH-stimulating efficacy and validated its ghrelin receptor-mediated mechanism, forming the pharmacological basis for comparing GHRPs in research and clinical contexts.
Growth hormone-releasing activity of a synthetic hexapeptide in normal volunteers and subjects with short stature
Journal of Clinical Endocrinology and Metabolism (1993) — PubMed
Demonstrated GHRP-6's ability to stimulate GH release in both healthy adults and GH-deficient subjects, with synergistic GH amplification when combined with GHRH, establishing the GHRP-plus-GHRH combination protocol that remains standard in research use.
GHRP-6 increases food intake in healthy subjects and patients with anorexia nervosa
Clinical Endocrinology (1994) — PubMed
Confirmed GHRP-6's potent appetite-stimulating effects in both healthy subjects and patients with anorexia nervosa, establishing the clinical rationale for its use in appetite restoration and cachexia management independent of its GH-stimulating properties.
Real-world data
GHRP-6 has a longer track record in research communities than any other GHRP, and the consensus is consistent: it delivers reliable GH stimulation but the appetite effect is the defining factor in whether a given user continues or switches to a different GHRP. Users in aggressive muscle-building phases often report that the appetite stimulation is their primary reason for choosing GHRP-6, allowing them to hit high caloric targets more easily.
Users in body recomposition or fat loss phases almost universally switch to GHRP-2 or ipamorelin after their first GHRP-6 cycle, as managing intense hunger during a caloric deficit is counterproductive. Sleep quality improvements and joint comfort are commonly reported at the pre-sleep dose, consistent with GHRP-6's well-established mechanism.
Get the GHRP-6 cheat sheet
Dosing quick-reference, key studies, and side effect management — in your inbox.
Frequently asked questions
Is the appetite stimulation from GHRP-6 always intense, or does it vary by dose?
The appetite effect is dose-dependent. At 100 mcg, most users report a noticeable but manageable hunger signal. At 200 to 300 mcg, the hunger becomes significantly more intense and harder to ignore. Timing injections immediately before planned meals is the most effective practical strategy for any dose. Users who find even the 100 mcg appetite effect unmanageable should consider GHRP-2 or ipamorelin instead.
Can GHRP-6 be used during a fat loss phase?
It is technically possible but practically difficult. The intense appetite stimulation directly conflicts with caloric restriction goals, making dietary compliance harder. GHRP-2 or ipamorelin are strongly preferred for fat loss phases because they provide GH stimulation with minimal appetite effects. GHRP-6 is best suited for bulking or maintenance phases where high caloric intake is the goal.
Does GHRP-6 cause more cortisol than GHRP-2?
Yes, based on published data and research community experience. Both peptides elevate cortisol transiently, but GHRP-6 tends to produce a more pronounced cortisol response at equivalent doses. For users concerned about cortisol, ipamorelin is the best option in the GHRP class, producing negligible cortisol changes at standard research doses.
What is the best way to stack GHRP-6 for maximum GH output?
Combining GHRP-6 with a GHRH analog such as CJC-1295 or modified GRF(1-29) produces the largest GH pulses because the two peptides work through complementary mechanisms. GHRP-6 suppresses somatostatin and activates pituitary GHS-R1a, while the GHRH analog amplifies GHRH signaling through a separate pituitary receptor. The combination produces GH pulses measurably larger than either peptide used alone, as established in clinical studies from the early 1990s (PMID: 7928953).
How does GHRP-6 compare to MK-677 as an oral alternative?
MK-677 (ibutamoren) is an oral ghrelin mimetic that replicates most of GHRP-6's mechanism without injections. The key differences are duration and pattern: MK-677 produces sustained GH and IGF-1 elevation across 24 hours rather than discrete pulses, and its appetite stimulation persists throughout the day rather than being tied to injection timing. MK-677 is the preferred alternative for users who want GHRP-6-style GH and appetite stimulation without daily injections, though its 24-hour appetite effect can also be harder to manage for some users.
Compare GHRP-6
Related peptides
Looking for weight loss peptides? See our complete guide to the best peptides for weight loss or compare semaglutide vs tirzepatide .
Get the Peptide Starter Kit (free)
Quick-start guide to GLP-1 peptides, dosing basics, and what to ask your doctor.
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional medical consultation, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol.